At the European Society for the Study of Diabetes (EASD) Annual Meeting in Barcelona, European Endocrinology editorial board member and EASD Senior Vice President and Chair Postgraduate Education Chantal Mathieu discusses the results of the highly anticipated VERIFY study and the latest advances in adjunct therapies in type 1 diabetes.
1. Can you summarise the results of the VERIFY study? (0:05)
2. How will this impact the future of Type 2 diabetes treatment? (1:56)
3. Is there added value to adding SGLT2 inhibitors to insulin therapy for people with type 1 diabetes? (2:50)
4. How can diabetic ketoacidosis be avoided in patients with type 1 diabetes being treated with an SGLT2 inhibitor? (4:10)
5. What are the major risks to the patients and how may these be overcome? (6:06)
Chantal Mathieu serves or has served on the advisory panel for Novo Nordisk, Sanofi, Merck Sharp and Dohme Ltd., Eli Lilly and Company, Novartis, AstraZeneca, Boehringer Ingelheim, Hanmi Pharmaceuticals, Roche, Medtronic, ActoBio Therapeutics, Pfizer, Dianax and UCB. Financial compensation for these activities has been received by KU Leuven; KU Leuven has received research support for CM from Medtronic, Novo Nordisk, Sanofi, Merck Sharp and Dohme Ltd., Eli Lilly and Company, Roche, Abbott, ActoBio Therapeutics and Novartis; CM serves or has served on the speakers bureau for Novo Nordisk, Sanofi, Merck Sharp and Dohme, Eli Lilly and Company, Boehringer Ingelheim, Astra Zeneca and Novartis. Financial compensation for these activities has been received by KU Leuven.
Filmed at the Annual Meeting of the European Association of the Study of Diabetes (EASD) Barcelona, Spain 2019.
Share this Video
Related Videos In Diabetes
Chantal Mathieu: Research highlights from 2022
We were delighted to speak with our editorial board member Prof. Chantal Mathieu (University Hospital Gasthuisberg Leuven, Leuven, Belgium) around this year’s research highlights in diabetes and what to look out for in 2023. Questions What are the key clinical highlights from 2022 in the field of diabetes? (0:16) What are the hot topics and […]
José García-Tirado, DTM 2022: RocketAP in Practice: Results from Pilot and Feasibility Trials
In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) gives an overview of RocketAP and discusses how the RocketAP compares to the USS-Virginia system and also what the next steps in the clinical development of the Rocket AP will be. The abstract entitled: ‘RocketAP in Practice: Results from Pilot and Feasibility […]
José García-Tirado, DTM 2022: Challenges in the development of artificial pancreas systems
An artificial pancreas is a system made of three parts that work together to mimic how a healthy pancreas controls blood glucose in the body. In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) discusses the major challenges in the development of artificial pancreas systems. The abstract entitled: ‘RocketAP in Practice: Results from Pilot […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!